Peripheral Leukocytes with HLA-DR+/CD8- Phenotype are Associated with Prognosis in Patients with Lung Cancer

Anticancer Research

Volumn 23, Issue 5 B, 2003, Pages 4149-4152

  Nakamura, Haruhiko ^a   Saji, Hisashi ^a   Aute, Idiris ^a   Kawasaki, Norihito ^a   Hosaka, Makoto ^a   Ogata, Akihiko ^a   Saijo, Takamoto ^a   Kato, Harubumi ^a  

^a TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

HLA DR; Human leukocyte antigen; Leukocyte; Lung cancer; Subset; Tumor immunity

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HELPER CELL; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SUPPRESSOR CELL;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLOW CYTOMETRY; HLA-DR ANTIGENS; HUMANS; IMMUNOPHENOTYPING; LUNG NEOPLASMS; MALE; PROGNOSIS; SURVIVAL RATE; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY;

EID: 0344872734     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Holmes E, Ramming K, Bein M, Coulson W and Callery C: Intralesional BCG immunotherapy of pulmonary tumors. J Thorac Cardiovasc Surg 77: 362-368, 1979.
2. Urist M, Boddie AJ, Townsend CJ and Holmes E: In vitro evidence for increased cellular immunity to lung cancer antigen during Levamisole immunotherapy. J Thorac Cardiovasc Surg 73: 189-194, 1977.
3. Holmes E and Golub S: Immunologic defects in lung cancer patients. J Thorac Cardiovasc Surg 71: 161-168, 1976.
4. Wanebo H, Rao B, Miyazawa N et al: Immune reactivity in primary carcinoma of the lung and its relation to prognosis. J Thorac Cardiovasc Surg 72: 339-350, 1976.
5. Dalbow M, Concannon J, Eng C, Weil C, Conway J and Narayanan NP: Lymphocyte mitogen stimulation studies for patients with lung cancer: evaluation of prognostic significance of preirradiation therapy studies. J Lab Clin Med 90: 295-302, 1977.
6. Braun D, Nisius S, Hollinshead A and Harris J: Serial immune testing in surgically resected lung cancer patients. Cancer Immunol Immunother 15: 114-120, 1983.
7. Lin C, Kuo Y, Huang W and Lin C: Natural killer cell activity in lung cancer patients. Chest 92: 1022-1024, 1987.
8. Chastang C, Lebeau B, Charpak Y and Decroix G: Prognostic factors from a randomized clinical trial in resected lung cancer. Stat Med 4: 279-85, 1985.
9. Nakamura H, Saji H, Ogata A et al: Immunologic parameters as significant prognostic factors in lung cancer. Lung Cancer 37: 161-169, 2002.
10. Mountain C: Revisions in the International System for staging lung cancer. Chest 111: 1710-1717, 1997.
11. Hershman M, Cheadle W, Wellhausen S, Davidson P and Polk H: Monocyte HLA-DR antigen expression characterizes clinical outcome in the trauma patient. Br J Surg 77: 204-207, 1990.
12. Cheadle W, Hershman M, Wellhausen S and Polk H: HLA-DR antigen expression on peripheral blood monocytes correlates with surgical infection. Am J Surg 161: 639-645, 1991.
13. Ditschkowski M, Kreuzfelder E, Rebmann V et al: HLA-DR expression and soluble HLA-DR levels in septic patients after trauma. Ann Surg 229: 246-254, 1999.
14. Zeromski J, Pietrzak J, Szmeja Z, Jezewska E, Gorny M and Kruk -ZA: Evaluation of phenotype of mononuclear host cells isolated from primary tumour and peripheral blood of patients with laryngeal carcinoma. Acta Otolaryngol (Stockh) 105: 149-154, 1988.
15. Kikuchi Y, Iwano I, Kita T et al: Changes of lymphocyte subsets in peripheral blood before and after operation of patients with advanced ovarian carcinoma. J Cancer Res Clin Oncol 116: 283-287, 1990.
16. Miyazaki K, Shimada K, Katabuchi H, Arakane F, Arao S and Okamura H: Activated (HLA-DR+) T-lymphocyte subsets in early epithelial ovarian cancer and malignant ovarian germ cell tumors. Gynecol Oncol 58: 362-367, 1995
17. + activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy. Int J Cancer 61: 470-474, 1995.
18. Becker S and Daniel E: Antagonistic and additive effects of IL-4 and interferon-gamma on human monocytes and macrophages: effects on Fc receptors, HLA-D antigens, and superoxide production. Cell Immunol 129: 351-362, 1990.
19. Gerrard T, Dyer D and Mostowski H: IL-4 and granulocyte-macrophage colony-stimulating factor selectively increase HLA-DR and HLA-DP antigens but not HLA-DQ antigens on human monocytes. J Immunol 144: 4670-4674, 1990.
20. + T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 42: 1-8, 1996.